PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: BoE expects strong UK growth in 2nd quarter

Thu, 06th May 2021 12:09

(Alliance News) - Stock prices in London were marginally higher at midday on Thursday in the wake of the Bank of England's latest interest rate decision, while US drugmakers were in focus after the Biden administration backed a plan to waive Covid-19 vaccine patents.

The central bank left the key UK interest rate unchanged at 0.1% and its quantitative easing programme untouched, with the total target stock of asset purchases at GBP895 billion.

The Bank of England said the outlook for the UK economy remains uncertain due to the virus pandemic. It predicted that gross domestic product will increase sharply in the second quarter but for growth slow thereafter as the boost from reopening wanes.

Following the BoE announcement, the pound was quoted at USD1.3902 at midday Thursday, down from USD1.3910 at the London equities close Wednesday.

Just prior to the announcement, FTSE 100 index was up 15.22 points, or 0.2%, at 7,054.52. The mid-cap FTSE 250 index was up 128.35 points, or 0.6%, at 22,514.25. The AIM All-Share index was down 0.6% at 1,254.10.

The Cboe UK 100 index was up 0.1% at 702.20. The Cboe 250 was up 0.7% at 20,205.81, and the Cboe Small Companies up 0.2% at 14,739.26.

In mainland Europe, the CAC 40 in Paris was down 0.1%, while the DAX 30 in Frankfurt was down 0.2%.

On the economic front, UK services sector activity growth hit a seven-and-a-half year high in April as lockdown restrictions eased, according to IHS Markit.

The IHS Markit/CIPS UK services purchasing managers' index was revised higher to 61.0 points in April from a preliminary estimate of 60.1, having registered 56.3 in March.

The latest reading signalled the fastest pace of expansion in the sector since October 2013.

In the FTSE 100, Next was the best performer, up 3.5%, after the high street and online retailer boosted its full-year profit guidance for a second time this year following a strong first quarter.

Next said full price sales were down 1.5% in the 13 weeks to May 1 on two years ago, before the Covid-19 pandemic, which the company said was a more "meaningful" comparison.

The FTSE 100 clothing and homewares retailer said it had assumed full-price sales during period would be down 10%, but beat this forecast by GBP75 million. As such, Next raised its central guidance for full-year pretax profit by GBP20 million to GBP720 million.

In April, the Leicester, England-based firm had raised its central profit guidance by GBP30 million to GBP700 million and "optimistically" ruled out further store closures as the UK's vaccine rollout continued.

Looking ahead, Next said it expects the recent post-lockdown sales surge to be short lived - based on the experience of last year - with sales to settle back toward guidance levels within the next few weeks.

Barratt Developments was up 2.0%. The housebuilder said it has performed well since the start of the calendar year reflecting underlying market strength and strong customer demand for "high-quality sustainable new homes".

For the period from January 1 to this past Sunday, total forward sales were GBP3.7 billion, up 31% from GBP2.83 billion at the same time in 2020, and it delivered 4,481 home completions, up 28% from 3,504.

The increase in completions in the period reflected the delivery of customers' homes in line with the UK government's original Help to Buy scheme and the stamp duty holiday deadlines, Barratt said.

Mexican miner Fresnillo was up 1.3%, tracking spot gold prices higher. The precious metal was quoted at USD1,793.58 an ounce Thursday midday, up from USD1,781.79 late Wednesday.

National Grid was up 1.2% after Berenberg raised the UK power lines operator to Buy from Hold.

Melrose Industries was up 1.0%. The industrial turnaround specialist said that, in the four months to April 30, trading was modestly ahead of expectations.

Melrose said the momentum seen in the second half of 2020 has continued into 2021, with sales in the period being 8% higher than in the same period in 2020. Excluding Nortek Air Management, group sales grew by 4%. Last month, Melrose agreed to sell Nortek Chicago-based Madison Industries for GBP2.62 billion.

Further, Melrose said operating margins achieved in the first quarter of the year continued to improve faster than expected, and cash generation has been encouraging, with Melrose "being cash neutral in the first quarter, in what is traditionally a cash outflow period".

Looking ahead, Melrose said it expects improvements in trading to continue, but noted the growth rate will be hindered by supply issues for semi-conductors in the global automotive supply chain.

At the other end of the large-caps, Mondi was the worst performer, down 4.1%. The packaging firm said it delivered a "robust performance" in the first quarter despite an expected decline in earnings.

Mondi reported underlying earnings before interest, tax, depreciation and amortisation of EUR353 million, down 8.3% from EUR385 million a year ago. This was in line with the company's expectations, however. Ebitda was up 14% from EUR309 million in the fourth quarter of last year.

Admiral Group, Polymetal International and Croda International were among the worst performers, down 3.5%, 3.0% and 2.9% respectively. The stocks went ex-dividend meaning new buyers no longer qualify for the latest payout.

The euro was priced at USD1.2049, up from USD1.2000. Against the yen, the dollar was trading at JPY109.13, down from JPY109.26.

Polling stations were open for voters to cast their ballots in a set of elections which could shake up British politics and have profound implications for the future of the UK.

On what has been dubbed 'Super Thursday', polling stations opened across Great Britain in the largest test of political opinion outside a general election, with the future of the Labour Party and the state of the Union among the issues at play.

Scottish National Party leader Nicola Sturgeon's push for a second independence referendum means the stakes are high in the Holyrood contest.

In England, as well as local council and mayoral contests, the Hartlepool parliamentary by-election will indicate what progress - if any - Labour has made in regaining votes in its former northern heartlands.

"For GBP, the Scottish parliamentary elections are certainly the one that investors will be watching. If the Scottish National Party manage to achieve a majority, the chances of a Scottish independence referendum is high. This result could negatively impact the British currency, as without Scotland, the British economy weakens," said analysts at OFX.

Brent oil was trading at USD68.70 a barrel at midday, down sharply from USD69.89 late Wednesday.

US stock market futures were pointed higher with the latest jobless claims numbers in focus ahead of the nonfarm payrolls report due on Friday.

The Dow Jones Industrial Average was called up 0.1%, the S&P 500 index up 0.1%, and the Nasdaq Composite up 0.3%.

US President Joe Biden's administration on Wednesday announced support for a global waiver on patent protections for Covid-19 vaccines, offering hope to poor nations that have struggled to access the life-saving doses.

US Trade Representative Katherine Tai said that while intellectual property rights for businesses are important, Washington "supports the waiver of those protections for Covid-19 vaccines" in order to end the pandemic.

Tedros Adhanom Ghebreyesus, head of the World Health Organization, called the US decision "historic" and marked "a monumental moment in the fight against Covid-19."

Patents give drugmakers a short-term monopoly on production to cover the high costs of research and development. Biotech firms have argued that these protections provided incentives to produce Covid-19 vaccines in a short period.

Tai in recent weeks has met with executives from all the major US vaccine producers - Pfizer, Moderna and Johnson & Johnson - to discuss the issue.

Pfizer, Moderna, Novavax and J&J shares were down 3.1%, 2.2%, 5.6% and 0.6% respectively in pre-market trade in New York. In London, AstraZeneca was up 0.7% in London, but BioNTech - partner of Pfizer on Covid-19 vaccines - was down 16% in Frankfurt.

The economic events calendar on Thursday has US jobless claims at 1330 BST.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more
3 Nov 2023 17:06

AstraZeneca plans next phase of trial on kidney drug combination data

(Alliance News) - AstraZeneca PLC on Friday touted results from a Phase IIb trial, which showed that a zibotentan and dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria.

Read more
3 Nov 2023 11:34

AstraZeneca's Lokelma lets kidney disease patients maintain therapy

(Alliance News) - AstraZeneca PLC on Thursday celebrated results from an observational study, which showed that treating hyperkalaemia with the potassium binder, Lokelma, allows chronic kidney disease and heart failure patients to maintain RAASi therapy.

Read more
2 Nov 2023 15:57

UK earnings, trading statements calendar - next 7 days

Friday 3 November 
no events scheduled 
Monday 6 November 
Kingspan Group PLCTrading Statement
Kosmos Energy LtdQ3 Results
Ryanair Holdings PLCHalf Year Results
Tuesday 7 November 
Associated British Foods PLCFull Year Results
Beazley PLCQ3 Results
Direct Line Insurance Group PLCTrading Statement
dotdigital Group PLCFull Year Results
IWG PLCQ3 Results
Persimmon PLCTrading Statement
RS Group PLCHalf Year Results
Vaalco Energy IncQ3 Results
Watches of Switzerland Group PLCTrading Statement
Wednesday 8 November 
Conduit Holdings LtdQ3 Results
ITV PLCTrading Statement
JD Wetherspoon PLCQ1 Results
Marks & Spencer Group PLCHalf Year Results
MaxCyte IncQ3 Results
Secure Trust Bank PLCTrading Statement
Smiths News PLCFull Year Results
Time Out Group PLCFull Year Results
Thursday 9 November 
3i Group PLCHalf Year Results
Apax Global Alpha LtdQ3 Results
AstraZeneca PLCQ3 Results
Auto Trader Group PLCHalf Year Results
B&M European Value Retail SAHalf Year Results
Domino's Pizza Group PLCTrading Statement
Endeavour Mining PLCQ3 Results
Flutter Entertainment PLCTrading Statement
IMI PLCTrading Statement
Indivior PLCQ3 Results
John Wood Group PLCTrading Statement
Lancashire Holdings LtdTrading Statement
National Grid PLCHalf Year Results
Regional REIT LtdTrading Statement
Renewi PLCHalf Year Results
S4 Capital PLCTrading Statement
Tate & Lyle PLCHalf Year Results
Taylor Wimpey PLCTrading Statement
TBC Bank Group PLCQ3 Results
TheWorks.co.uk PLCTrading Statement
Trakm8 Holdings PLCHalf Year Results
Urban Logistics REIT PLCHalf Year Results
Vistry Group PLCTrading Statement
WH Smith PLCFull Year Results
Wincanton PLCHalf Year Results
Wizz Air Holdings PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
1 Nov 2023 08:59

AstraZeneca launches collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Wednesday announced a new collaboration and investment agreement with clinical-stage biotechnology company Cellectis.

Read more
1 Nov 2023 07:33

AstraZeneca invests $220m in French gene-editing group Cellectis

(Sharecast News) - AstraZeneca is to invest in French biopharma group Cellectis to use its gene-editing technologies to develop next-gen therapeutics in areas like oncology, immunology and rare diseases.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.